Skip to content

The Application of a Biphasic Calcium Sulfate Graft Material in Sinus Floor Elevation

The Application of a Biphasic Calcium Sulfate Graft Material in Sinus Floor Elevation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06533397
Enrollment
40
Registered
2024-08-01
Start date
2024-08-24
Completion date
2031-09-01
Last updated
2026-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alveolar Bone Loss, Edentulism Nos

Keywords

bone graft material, biphasic calcium sulfate, sinus floor elevation, sinus lift, maxillary sinus augmentation, microcomputed tomography, cone beam computed tomography, histology, histomorphometry, dental implant

Brief summary

Pneumatization of the maxillary sinus may lead to insufficient bone volume for dental implant placement in the edentulous posterior maxilla. Sinus floor elevation (SFE) surgery with the lateral window technique is a safe and predictable surgical intervention to restore bone height in the maxillary premolar and molar areas. According to the literature, several bone graft materials may be successfully applied for SFE surgery. There is a lack of evidence regarding the application of biphasic calcium sulfate (BCS) for SFE. The healing period following staged SFE is 2-9 months. The aim of this study is: * to evaluate the success of SFE surgery using BCS as graft material, * to compare the microarchitecture of the augmented bone depending on the healing period, * to evaluate the success of dental implants placed in the augmented bone and that of the prostheses delivered on the dental implants.

Interventions

PROCEDURESinus floor elevation (SFE)

Patients rinse with 0.2% chlorhexidine solution for one minute before surgery. Under local anesthesia, a mucoperiosteal flap is raised from a midcrestal incision and two relieving incisions. Lateral window osteotomies are carried out using diamond burs. The Schneiderian membrane is carefully elevated and the synthetic bone graft material (Bond Apatite, Augma Biomaterials, Cesarea, Israel) (2-3 cm3) is packed in the defect with light force. The buccal flap is then mobilized to allow tension-free primary closure. The margins are stabilized with single interrupted sutures. Antibiotics (1 g amoxicillin-clavulanate twice a day for 5 days, or in case of side effects or known allergy to penicillin, 300 mg clindamycin 4 times a day for 4 days), anti-inflammatory drugs (50 mg diclofenac 3 times a day for 3 days), and chlorhexidine mouthwash (twice a day for 21 days from the first day after surgery) are prescribed. Suture removal takes place after 10 days.

A CBCT scan is performed before SFE surgery to evaluate the anatomy and pathologies of the maxillary sinus.

DIAGNOSTIC_TESTpostoperative CBCT

A CBCT scan is performed following the 3- or 6-month-long healing period after SFE to evaluate the anatomy and healing of the augmented bone and the maxillary sinus.

DIAGNOSTIC_TESTbone core biopsy

At the time of dental implant placement, the first step of the implant bed preparation is performed using a trephine drill to harvest a bone core biopsy sample from the augmented bone. The biopsy sample is harvested from the implant bed, this way the patient is spared of excess surgical burden as this bone would be removed even if no biopsy sample was harvested during dental implant placement. The bone core biopsy samples are subjected to histomorphometric and microCT analysis.

PROCEDUREdental implant placement

Following the 3- or 6-month-long healing period following SFE, dental implants are placed non-submerged in the augmented bone under local anesthesia.

3 months after dental implant placement, fixed dental prostheses are delivered on the dental implants.

A synthetic bone graft material (Bond Apatite, Augma Biomaterials, Cesarea, Israel) is used during SFE.

Sponsors

Semmelweis University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients over the age of 18 years, * Patients who need dental implant-borne prostheses, * Patients with insufficient bone height in the posterior maxilla due to sinus pneumatization.

Exclusion criteria

.• Patients who had major systemic diseases as classified by the American Society of Anesthesiologists (ASA grades III-IV), * psychiatric contraindications, * patients on medication interfering with bone metabolism, including steroid therapy and antiresorptive medication, * radiation to the head or neck region within the previous five years, * localized periapical disease, odontogenic and nonodontogenic cysts, and maxillary sinusitis, * evidence of uncontrolled periodontal disease, * Alcohol Use Disorder defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), * recreational drug abuse, * heavy smoking (\>10 cigarettes/day), * diseases of the oral mucosa, including blisters and ulcers, i.e.: red and white lesions, pigmented lesions, benign tumors of the oral cavity, and oral cancer. Leukoplakia, Erythroplakia, Precancerous lesions, Oral squamous cell carcinoma and malign tumors of the soft and hard tissues, Oral candidiasis, Oral lichen planus, Psoriasis, Pemphigus, and Pemphigoid. * pregnancy or nursing, * poor oral hygiene

Design outcomes

Primary

MeasureTime frameDescription
Success of the SFE3 or 6 monthsThe SFE surgery is successful if no inflammatory complications occur in the 3- or 6-month-long healing period and the bone volume is sufficient for dental implant placement.
Success of the dental implants5 yearsAccording to The International Congress of Oral Implantologists (ICOI) Pisa Consensus Conference. Success (optimum health) 1. No pain or tenderness upon function 2. 0 mobility 3. less than 2 mm radiographic bone loss from initial surgery 4. No exudates in the patient's history II. Satisfactory survival 1. No pain on function 2. 0 mobility 3. 2-4 mm radiographic bone loss 4. No exudates in the patient's history III. Compromised survival 1. May have sensitivity on function 2. No mobility 3. Radiographic bone loss of more than 4 mm (less than1/2 of the length of the implant body) 4. Probing depth more than 7 mm 5. May have exudates in the patient's history IV. Failure (clinical or absolute failure) Any of the following: 1. Pain on function 2. Mobility 3. Radiographic bone loss of more than 1/2 length of the implant 4. Uncontrolled exudate 5. Implant no longer in mouth
Success of the implant borne prostheses5 yearsProstheses with four or fewer complications (screw loosening, decementation, chipping) that could be treated chairside.

Secondary

MeasureTime frameDescription
Hisomorphometry: Percent of residual bone graft particles3-6 monthsThe percentage of residual bone graft particle-area measured on the representative sections prepared from the bone core biopsy samples. Unit: percent (%)
Hisomorphometry: Percent of newly formed bone3-6 monthsThe percentage of newly formed bone-area measured on the representative sections prepared from the bone core biopsy samples. Unit: percent (%)
Hisomorphometry: Percent of bone marrow3-6 monthsThe percentage of bone marrow-area measured on the representative sections prepared from the bone core biopsy samples. Unit: percent (%)
Value of the percent bone volume (BV/TV) calculated from the microCT reconstructions of the bone core biopsy samples.3-6 monthsRelative volume of calcified tissue in the selected volume. Unit: none
Value of the bone surface to volume ratio (BS/TV), calculated from the microCT reconstructions of the bone core biopsy samples.3-6 monthsRatio of the segmented bone surface to the total volume in the region of interest. Unit: 1/mm
Value of the trabecular thickness (Tb.Th.), calculated from the microCT reconstructions of the bone core biopsy samples.3-6 monthsMean thickness of the trabeculae, assessed using direct 3D methods. Unit: mm
Value of the trabecular separation (Tb.Sp.), calculated from the microCT reconstructions of the bone core biopsy samples.3-6 monthsMean distance between the trabeculae, assessed using direct 3D methods. Unit: mm
Value of the trabecular bone pattern factor (Tb.Pf), calculated from the microCT reconstructions of the bone core biopsy samples.3-6 monthsIndicator of the relation between convex and concave elements in the trabecular bone structure. Tb.Pf \<0 when the trabecular bone is honeycomb-like and increases as the trabecular bone acquires a rod-like structure. Unit: none
Value of the structure model index (SMI), calculated from the microCT reconstructions of the bone core biopsy samples.3-6 monthsThe estimator of the plate- versus rod-like characteristic of the trabecular bone structure, 0 for perfect plates, 3 for perfect rods, and 4 for perfect spheres. Unit: none
Value of the Total porosity (Po(tot)), calculated from the microCT reconstructions of the bone core biopsy samples.3-6 monthsPercent porosity is the volume of pores as a percent of the total volume of interest (VOI). Unit: percent (%)
Value of the Connectivity (Conn.), calculated from the microCT reconstructions of the bone core biopsy samples.3-6 monthsOne useful and fast algorithm for calculating the Euler connectivity in 3D is the "Conneulor". It measures what might be called "redundant connectivity", the degree to which parts of the object are multiply connected. It is a measure of how many connections in a structure can be severed before the structure falls into two separate pieces. Unit: none.

Countries

Hungary

Contacts

CONTACTMárton Kivovics, DMD,MSD,PHD
kivovics.marton@semmelweis.hu003614591500
CONTACTDorottya Pénzes, DMD,MSD,PHD
dorottya.penzes@semmelweis.hu003614591500
PRINCIPAL_INVESTIGATORMárton Kivovics, DMD,MSD,PHD

Department of Public Dental Health, Semmelweis University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 25, 2026